

Manuel Vaz Silva

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3526573/publications.pdf>

Version: 2024-02-01

30
papers

871
citations

566801

15
h-index

552369

26
g-index

31
all docs

31
docs citations

31
times ranked

1322
citing authors

#	ARTICLE	IF	CITATIONS
1	Pharmacokinetic and safety profile of <i>trans</i> -resveratrol in a rising multiple-dose study in healthy volunteers. <i>Molecular Nutrition and Food Research</i> , 2009, 53, S7-15.	1.5	363
2	Why healthy subjects volunteer for phase I studies and how they perceive their participation?. <i>European Journal of Clinical Pharmacology</i> , 2007, 63, 1085-1094.	0.8	65
3	Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations. <i>European Journal of Clinical Pharmacology</i> , 2014, 70, 1059-1071.	0.8	58
4	Effect of Food on the Pharmacokinetic Profile of Eslicarbazepine Acetate (BIA 2-093). <i>Drugs in R and D</i> , 2005, 6, 201-206.	1.1	48
5	Effect of eslicarbazepine acetate on the pharmacokinetics of a combined ethinylestradiol/levonorgestrel oral contraceptive in healthy women. <i>Epilepsy Research</i> , 2013, 105, 368-376.	0.8	39
6	Pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine at steady state in healthy volunteers. <i>Epilepsia</i> , 2013, 54, 1453-1461.	2.6	38
7	Etamicastat, a Novel Dopamine β -Hydroxylase Inhibitor: Tolerability, Pharmacokinetics, and Pharmacodynamics in Patients With Hypertension. <i>Clinical Therapeutics</i> , 2013, 35, 1983-1996.	1.1	29
8	Evaluation of Eslicarbazepine Acetate on Cardiac Repolarization in a Thorough QT/QTc Study. <i>Journal of Clinical Pharmacology</i> , 2012, 52, 222-233.	1.0	27
9	Bioavailability and Bioequivalence of Two Enteric-Coated Formulations of Omeprazole in Fasting and Fed Conditions. <i>Clinical Drug Investigation</i> , 2005, 25, 391-399.	1.1	26
10	Effect of eslicarbazepine acetate on the pharmacokinetics of digoxin in healthy subjects. <i>Fundamental and Clinical Pharmacology</i> , 2009, 23, 509-514.	1.0	26
11	Safety, Tolerability, and Pharmacokinetics of Etamicastat, a Novel Dopamine β -Hydroxylase Inhibitor, in a Rising Multiple-Dose Study in Young Healthy Subjects. <i>Drugs in R and D</i> , 2010, 10, 225-242.	1.1	23
12	Pharmacokinetic-pharmacodynamic interaction between BIA 3-202, a novel COMT inhibitor, and levodopa/benserazide. <i>European Journal of Clinical Pharmacology</i> , 2003, 59, 603-609.	0.8	22
13	Single-Dose Tolerability, Pharmacokinetics, and Pharmacodynamics of Etamicastat (BIA 5-453), a New Dopamine β -Hydroxylase Inhibitor, in Healthy Subjects. <i>Journal of Clinical Pharmacology</i> , 2012, 52, 156-170.	1.0	21
14	Pharmacokinetic-Pharmacodynamic Interaction Between BIA 3-202, a Novel COMT Inhibitor, and Levodopa/Carbidopa. <i>Clinical Neuropharmacology</i> , 2004, 27, 17-24.	0.2	15
15	Pharmacokinetics and Tolerability of Etamicastat Following Single and Repeated Administration in Elderly Versus Young Healthy Male Subjects: An Open-Label, Single-Center, Parallel-Group Study. <i>Clinical Therapeutics</i> , 2011, 33, 776-791.	1.1	15
16	Pharmacokinetic-pharmacodynamic interaction between nebicapone and controlled-release levodopa/benserazide: A single-center, phase I, double-blind, randomized, placebo-controlled, four-way crossover study in healthy subjects. <i>Clinical Therapeutics</i> , 2009, 31, 2258-2271.	1.1	13
17	Alterações eletrocardiográficas benignas e patológicas em atletas. <i>Revista Portuguesa De Cardiologia</i> , 2015, 34, 753-770.	0.2	9
18	Effect of Food on the Pharmacokinetic Profile of Etamicastat (BIA 5-453). <i>Drugs in R and D</i> , 2011, 11, 127-136.	1.1	7

#	ARTICLE	IF	CITATIONS
19	Effect of nebicapone on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. <i>European Journal of Clinical Pharmacology</i> , 2008, 64, 961-966.	0.8	6
20	Chronopharmacology of nebicapone, a new catechol-O-methyltransferase inhibitor. <i>Current Medical Research and Opinion</i> , 2010, 26, 1097-1108.	0.9	5
21	Pharmacokinetic-Pharmacodynamic Interaction between Nebicapone, a Novel Catechol-O-Methyltransferase Inhibitor, and Controlled-Release Levodopa/Carbidopa 200Âmg/50Âmg. <i>Drugs in R and D</i> , 2008, 9, 435-446.	1.1	4
22	Cardiac safety profile of etamicastat, a novel peripheral selective dopamine- β -hydroxylase inhibitor in non-human primates, human young and elderly healthy volunteers and hypertensive patients. <i>IJC Metabolic & Endocrine</i> , 2015, 7, 10-24.	0.5	4
23	Unusual type A aortic dissection. <i>Revista Portuguesa De Cardiologia</i> , 2012, 31, 175-176.	0.2	2
24	MONITORIA: The start of a new era of ambulatory heart failure monitoring? Part II “ Design. <i>Revista Portuguesa De Cardiologia</i> , 2021, 40, 343-351.	0.2	2
25	Peripheral arterial tonometry as a method of measuring reactive hyperaemia correlates with organ dysfunction and prognosis in the critically ill patient: a prospective observational study. <i>Journal of Clinical Monitoring and Computing</i> , 2021, 35, 1169-1181.	0.7	1
26	MONITORIA: The start of a new era of ambulatory heart failure monitoring? Part I “ Theoretical Rationale. <i>Revista Portuguesa De Cardiologia</i> , 2021, 40, 329-337.	0.2	0
27	Abstract 358: Signature microRNA Expression Pattern of Essential Hypertension in a Portuguese Population. <i>Hypertension</i> , 2012, 60, .	1.3	0
28	Identifications of Novel SNPs in Portuguese Essential Hypertensive Patients. <i>FASEB Journal</i> , 2013, 27, 874.14.	0.2	0
29	Analysis of MicroRNA Expression Profile in PBMCs of Hypertensive Patients. <i>FASEB Journal</i> , 2013, 27, 737.3.	0.2	0
30	Effects of enalapril and imidapril in the capsaicin cough challenge test and spirometry parameters in healthy volunteers. <i>Therapy: Open Access in Clinical Medicine</i> , 2004, 1, 223-230.	0.2	0